Pacific Biosciences vs Cognito Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Pioneer of single-molecule real-time (SMRT) long-read sequencing; Revio system targets clinical and research markets. Guides to $150–$170M FY2025 revenue with 40%+ gross margins.
About
Pacific Biosciences (PacBio) was founded in 2004 in Menlo Park, California and pioneered single-molecule real-time (SMRT) sequencing technology, enabling long-read DNA sequencing that can span tens of thousands of base pairs per read. This capability is essential for resolving complex genomic regions—structural variants, repeat expansions, methylation patterns, and full-length transcripts—that short-read platforms like Illumina cannot accurately assemble.\n\nPacBio's Revio system, launched in 2023, offers a dramatic improvement in throughput and cost efficiency over prior instruments, targeting both research and clinical sequencing laboratories. Key applications include rare disease diagnosis, pharmacogenomics, plant and animal genomics, and clinical oncology. The company guides to $150–$170 million in FY2025 revenue with gross margins exceeding 40% and a path to cash flow breakeven by 2027.\n\nPacBio competes primarily with Oxford Nanopore Technologies in the long-read segment, together driving adoption of long-read sequencing for comprehensive genome assembly and clinical applications. The company is expanding its high-accuracy (HiFi) chemistry and developing Onso, a short-read system, to capture a broader share of the sequencing market. With approximately $260 million in cash, PacBio is well-positioned to scale its clinical business.
Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.
About
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.